Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Infection with COVID-19 has resulted in over 276,000 deaths in the United States and over 1.5 million deaths globally, with upwards of 15% of patients requiring hospitalization. The majority of patients with COVID-19 experience upper respiratory symptoms, weakness, and fatigue, with anosmia and dysgeusia reported in some instances. Moderate (i.e., requiring hospitalization) and severe (i.e., requiring intensive care unit (ICU) level of care – ventilation and/or pressors) manifestations of COVID-19 include acute respiratory distress syndrome (ARDS) and new incident heart failure. Interestingly, the pediatric manifestation of severe COVID-19, known as pediatric multisystem inflammatory syndrome (PMIS), shares features with Kawasaki disease, a medium-vessel vasculitis observed in children, and Kawasaki shock syndrome, highlighted by coronary microvascular dysfunction. The clearly dichotomous presentation of severe disease in adult and pediatric populations highlights the interesting biological role of the microvasculature in COVID-19.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the etiologic agent of COVID-19, invades host cells via the ACE2 receptor by binding of viral surface spike (S) protein, suggestive of the role of endothelial dysfunction in disease manifestation. Thus, essential to the pathogenesis of severe COVID-19 is microvascular dysfunction, systemic inflammation, and cytokine storm. At its etiologic root, COVID-19 triggers endothelial exocytosis, which results in microvascular thrombosis and inflammation. In fact, laboratory findings of patients with severe COVID-19 are consistent with hypercoagulability, hallmarked by elevated D-Dimer, von Willebrand Factor (VWF), and Factor VIII, clinically identified as “COVID-Coagulopathy”. The contention that severe COVID-19 infection is a disease of the microcirculation has been emphasized throughout the course of the pandemic, particularly due to the clinical manifestation of severe infection. In fact, it has been hypothesized and shown in particular instances that microvascular function is a significant prognosticator for morbidity and mortality.

More recently, the role of nitric oxide signaling and dysfunction of the endothelial glycocalyx has come to the forefront of the discussion of the microvascular pathogenesis of COVID-19. The objective of this review is to provide mechanistic background for the microvascular nature of severe COVID-19 infection, with a particular emphasis on dysfunction of the endothelial glycocalyx and nitric oxide mediated pathogenesis.
comparison of differences in the clinical manifestation of microvascular dysfunction in adult and pediatric populations. Next, we provide a discussion of the pathophysiologic and molecular basis for microvascular dysfunction in COVID-19, discussing the role of endothelial glycocalyx injury as well as the role of nitric oxide in propagating systemic inflammation. We conclude by discussing potential interventions related to nitric oxide in COVID-19, with a brief discussion on the potential of nitric oxide releasing nanoparticles for combatting systemic inflammation (Figure 1).

**Clinical manifestations of microvascular dysfunction in COVID-19**

The clinical manifestation of severe COVID-19 results from systemic inflammation and thrombosis. Mechanistically, COVID-19 is known to trigger endothelial cell exocytosis, which drives microvascular inflammation and thrombosis. Subsequently, microvascular thrombosis drives the clinical phenotype of severe COVID-19 in the ICU, namely venous thromboembolism (VTE) and deep vein thrombosis (DVT) and related complications. Serum inflammatory markers in severe COVID-19, including elevated C-reactive protein, interleukin 6 (IL-6), increased fibrinogen, and elevated erythrocyte sedimentation rate (ESR), are consistent with cytokine storm, further highlighting the role of systemic inflammation in disease pathogenesis. These clinical observations highly suggest that microvascular inflammation is the primary mediator of systemic inflammation in these patients.

COVID-19 is, in its essence, a microvascular disease, in which direct infection by the SARS-CoV2 virus triggers endothelial injury resulting in endothelial exocytosis. Endothelial exocytosis directly results in microvascular thrombosis and microvascular inflammation, which in turn progress into systemic thrombosis and inflammation. During exocytosis, endothelial cells release VWF and P-selectin from granules, known as Weibel-Palade bodies. P-selectin interacts with VWF, which is one mechanism of COVID-19 related thrombosis. There are three primary mechanisms of viral mediated endothelial exocytosis:

1. Viral attachment to receptors on endothelial cells, including ACE2-R (Angiotensin-Converting Enzyme 2-Receptor)
2. Indirect activation of exocytosis
3. Direct infection of endothelial cells with viral peptides

Recent studies have identified that in the context of systemic SARS-CoV2 infection, viral attachment and entry via the ACE2-R is the primary mechanism of viral mediated exocytosis. These studies have only further cemented the idea that COVID-19 initiates a cycle of microvascular dysfunction followed by endothelial
Patients with comorbid cardiovascular disease (CVD) are at a uniquely increased risk of severe COVID-19 infection, which requires ICU hospitalization and results in high short-term mortality. The mechanism underlying this association is unclear, though arterial and venous thrombosis and vascular inflammation are likely mediators. Furthermore, the SARS-CoV2 virus itself can cause myocarditis and myocardial injury by an unknown mechanism; however, it has been suggested that SARS-CoV2 is able to infect endothelium within the myocardium and even cardiomyocytes. The suggested mechanism involves the presence of ACE2-R on both endothelium and cardiomyocytes, though direct infection in cardiomyocytes has only been demonstrated in induced pluripotent stem cells. Clinical evidence of myocardial injury includes subclinical elevation of high sensitivity troponins, which have been associated with increased mortality in COVID-19 patients, and subclinical elevation of N-terminal pro brain natriuretic peptide (NT-proBNP). Whether elevated troponins and NT-proBNP result from direct myocardial injury or myocardial injury secondary to endothelial disruption and impaired microvascular compliance is unknown. Recently, however, the MYSTIC study of microvascular dysfunction in COVID-19 found, in a small cohort, that indices of endothelial dysfunction, namely ADAMTS-13, a VWF protease, and VEGF-A, better predicted mortality compared with indices of myocardial injury. In fact, ADAMTS-13 inversely correlated with COVID-19 severity. These data suggest that the pathogenesis of severe COVID-19 is rooted in microvascular dysfunction. Taken together, there exists a dichotomy in the presentation of cardiovascular complications secondary to COVID-19 infection involving both direct myocardial injury and endothelial dysfunction (Figure 1).

Contrasted with adults, the manifestation of COVID-19 in pediatrics, though rare, is known as the pediatric multisystem inflammatory syndrome (PMIS), which shares numerous features with Kawasaki Disease. Symptoms of PMIS are diverse and have included rash or conjunctivitis, hypotension or shock, myocardial dysfunction, coagulopathy, or gastrointestinal symptoms, and elevated markers of inflammation. Furthermore, PMIS is associated with a systemic cytokine storm and inflammatory shock and is known to behave as a microvascular angiopathy. Whether PMIS is associated with myocardial perfusion defects secondary to coronary microvascular dysfunction is unknown and is an area of future research.

The pathophysiology of microvascular dysfunction in COVID-19 and ARDS

COVID-19 is a microvascular disease that has systemic implications beyond the pulmonary system and ARDS. At the root of the ARDS and organ failure seen in COVID-19 are endothelial dysfunction and vascular leak. Studies of the assessment of microvascular hemodynamics in vivo in COVID-19 have provided insight into its pathophysiology. In the MYSTIC study, up to a 90% decrease in capillary (4-6 μm) density and a reduction of red blood cell velocity was observed in sublingual microscopy of COVID-19 patients. Furthermore, vascular densities of vessels with 4-10 μm in COVID-19 patients with and without ventilation were shown to decrease compared to the control group. However, no such difference was observed for vessels > 10 μm, suggesting microvascular dysfunction in COVID-19 is restricted to capillaries. Of note, in this same study, perfused boundary region (PBR), an index of glycocalyx injury, was elevated in COVID-19 patients regardless of mechanical ventilation, though more dramatically elevated in patients requiring mechanical ventilation. COVID-19 is also thought to increase glycocalyx permeability and mediate glycocalyx thinning, with levels of hyaluronic acid and syndecan-1 correlating with need for ventilation. Taken together, these results suggest that dysfunction of the endothelial glycocalyx independently associates with disease severity.

Severe COVID-19 infection is hallmarked by changes in microvascular hemodynamics, oxygenation, angiogenesis, and thrombogenesis. Indices of microvascular function, namely ADAMST13, VEGF-A, PBR, and Angpt-2, better predicted mortality in COVID-19 over a 60-day hospitalization compared with classic indices of myocardial injury and inflammation. Furthermore, capillary loss seen via sublingual microscopy correlated with oxygenation levels, SOFA, and SIC scores, further demonstrating the value of microvascular function in assessing COVID-19 patients. Postmortem analysis of pulmonary capillaries in COVID-19 demonstrated capillary plugging from fibrous microthrombi, suggesting systemic thrombosis is a primary mechanism of pulmonary COVID-19 infection. An increase in Angpt-2 in COVID-19 patients especially those on mechanical ventilation suggests that Angpt-2 mediated endothelial leak is a predominant effect of COVID-19 on the microcirculation. In this same study, dysregulated angiogenesis, indicated by an increase in VEGF-A and sFLT1, further demonstrated that COVID-19 results in microvascular dysfunction. Thus, it is clear that COVID-19 infection results in significant changes in microvascular hemodynamics and angiogenesis, further supporting the hypothesis that severe COVID-19 infection is truly a disease of the microcirculation.

Given the microvascular nature of severe COVID-19 infection, there has been much interest in nitric oxide-based therapies to limit viral load within the lungs to prevent and treat ARDS and acute lung injury. Prior to discussing the role of nitric oxide (NO) in severe COVID-19 and ARDS, we will first provide a brief overview of microvascular dysfunction in ARDS. The mechanism of ARDS secondary to pulmonary infection involves a hypothesized loss of surfactant,
resulting in end-expiratory alveolar collapse and reduction in lung compliance. Histologically, ARDS is defined by three phases: (1) acute phase, or diffuse alveolar damage (DAD), which includes alveolar edema, hyaline membranes, and thickened alveolar septae, (2) proliferative phase, and (3) fibrotic phase. From Starling forces, this results in increased fluid conductance and pulmonary edema, which is not pressure driven, contrary to cardiogenic pulmonary edema. Alveolar edema in ARDS results in ventilation/perfusion (V/Q) mismatch and subsequent hypoxemia. Treatment involves oxygen to maintain arterial oxygen saturation and positive end-expiratory pressure (PEEP) to increase pulmonary compliance. In the context of COVID-19 infection, attachment to respiratory epithelium by the ACE2-R is thought to be the primary cause for ARDS secondary to inflammation and cytokine storm (Figure 1).

NO is critical in the pathogenesis of ARDS, particularly with regard to systemic hypoxemia and endothelial dysfunction, independent of impaired alveolar oxygen diffusion and endothelial exocytosis. In particular, a decreased nitric oxide/reactive oxidation species (NO/ROS) ratio is known to result in M1 macrophage activation and erythrocyte membrane damage. Hemoglobin released from damaged erythrocytes scavenges endothelial NO and contributes to oxidative stress, hypoxia, and endothelial dysfunction. NO mediated transformation of M1 macrophages to M2 macrophages may be useful in preventing this cascade in the context of acute lung injury and ARDS in severe COVID-19 infection. Furthermore, when ARDS is present, NO has been shown to improve arterial oxygenation by improving V/Q mismatch independent of PEEP. As elderly patients, patients with cardiovascular disease, and patients with microvascular complications from diabetes are known to have decreased endogenous NO production and are known to more likely have severe COVID-19 infection, supplementation with NO may help in improving mortality and reducing hospitalization in these susceptible populations. Thus, the critical nature of NO in systemic endothelial dysfunction and hypoxemia makes it an attractive target for treatment of severe COVID-19 infection.

Nitric oxide based therapies in COVID-19
Most NO based therapies are still under development and have recently increased in prevalence and testing particularly due to their potential ability to help reduce mortality in severe COVID-19 infection and ARDS. Currently, there are two primary mechanisms for NO delivery that have been developed: (1) inhaled NO and (2) NO releasing nanoparticles. In prior studies, inhaled NO was not shown to reduce mortality in ARDS. This is likely due to decreased bioavailability secondary to increased alveolar septae thickness and DAD observed in ARDS. Within the COVID-19 pandemic, two inhalation NO therapies, Bellerophon Therapeutics INOpulse and VERO Biotech’s GENOSYL DS inhaled NO have been evaluated for severe infection. While one study has demonstrated improvement in symptoms in outpatient COVID-19, whether these therapeutics have an influence on mortality in severe COVID-19 is yet to be seen. NO releasing nanoparticles have shown much promise for limiting inflammation, preventing ischemia reperfusion, and more recently, has demonstrated improved microvascular perfusion in an animal model of sepsis. However, to date, no trials have been performed with NO releasing nanoparticles. In summary, despite the promise of NO based therapies for combating systemic inflammation and sepsis, particularly in COVID-19, further translational development is required before assessing clinical impact.

SUMMARY
In severe COVID-19, microvascular function is a significant prognosticator for morbidity and mortality. Initially thought to be isolated to the pulmonary system and result in ARDS, patients with COVID-19 have been observed to have acute cardiac, renal, and thrombotic complications. Sequalae from systemic thrombosis, namely stroke and pulmonary embolism, have also been reported. Therefore, severe COVID-19 is a vascular disease that has systemic implications. Due to the vascular nature of severe COVID-19, its effect on the microcirculation has been of great interest. Clinical manifestations of severe COVID-19 include systemic inflammation and coagulopathy, namely venous thromboembolism and deep vein thrombosis. Moreover, the clinical manifestations of severe COVID-19 may differ in adult and pediatric populations. Consistent with this observation is the manifestation of pediatric multisystem inflammatory syndrome (PMIS), which shares many features with Kawasaki syndrome. Importantly, functional capillary densities were shown to decrease upon infection with COVID-19, suggesting changes in microvascular hemodynamics consistent with COVID-19 being a microvascular disease. Mechanistically, the microvascular nature of severe COVID-19 infection described here emphasized endothelial exocytosis, endothelial glycolalx dysfunction, and nitric oxide mediated pathogenesis focusing on the role of nitric oxide signaling in ARDS. Severe COVID-19 was shown to increase glycolalx thinning and permeability. Furthermore, RBC injury in COVID-19 results in hemoglobin mediated nitric oxide scavenging which may result in hypoxia, endothelial dysfunction, and oxidative stress. Particularly in COVID-19 induced ARDS, NO based therapy may improve arterial oxygenation independent of ventilation. Potential interventions related to nitric oxide, specifically nitric oxide releasing nanoparticles, in COVID-19 may be therapeutic in treating severe infection.

CONCLUSIONS
Severe COVID-19 is a systemic disease of the microcirculation. Despite much of the work into the
Microvascular dysfunction in severe COVID-19 infection

Microvascular effects of COVID-19, many open questions still remain. For instance, with respect to cardiovascular injury, whether elevated troponins and NT-proBNP result from direct myocardial injury or myocardial injury secondary to endothelial disruption and impaired microvascular compliance is unknown. Furthermore, the pathophysiology of PMIS in children is unclear, with few management options. Management of severe COVID-19 remains limited to ventilatory support and pressors. NO based therapies have shown much promise, though future development is required before clinical implementation. In summary, the COVID-19 pandemic has paved the way for advancements in NO based and microcirculation specific therapies, with significant translational advances still required prior to clinical impact.

DECLARATION OF COMPETING INTEREST

There are no potential conflicts of interest, real or perceived, by the authors.

REFERENCES

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534.
2. Grant MC, Geoghegan L, Arbyn M, et al. The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries. 2020. Available at SSRN 3582819.
3. Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: a review based on up-to-date knowledge. Am J Otalaryngol. 2020 102581.
4. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet North Am Ed. 2020.
5. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocaris P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet North Am Ed. 2020;395(10327):1607–1608.
6. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structural, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020.
7. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Basic structure for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367 (6483):1444–1448.
8. Colantuoni A, Martini R, Caprari P, et al. COVID-19 sepsis and microcirculation dysfunction. Front Physiol. 2020;11:747.
9. Lowenstein CJ, Solomon SD. Severe COVID-19 is a microvascular disease. Circulation. 2020;142(17):1610–1611.
10. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet North Am Ed. 2020;395(10234):1417–1418.
11. Klook F, Krupi M, Van der Meer N, et al. Incidence of thrombotic complications in critically ill COVID19 patients with COVID-19. Thromb Res. 2020.
12. Gebicki J, Kataryzynska J, Marcinek A. Can the microcirculatory response to hypoxia be a prognostic factor for Covid-19? Respir Physiol Neurobiol. 2020.
13. Rosas A, Osiaev I, Buscher K, et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis. 2020;1–13.
14. Adsumilli NC, Zhang D, Friedman JM, Friedman AJ. Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19. Nitric Oxide. 2020.
15. Okada H, Yoshida S, Hara A, Ogura S, Tornita H. Vascular endothelial injury exacerbates coronavirus disease 2019: the role of endothelial glycoalyx protection. Microcirculation. 2020;27:12653.
16. Goshua G, Pine AB, Meizlish ML, et al. Endotheliochip in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575–e582.
17. O’Sullivan JM, Mc Gonagle D, Ward SE, Preston RJ, O’Donnell JS. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol. 2020; 7(8):e653–e655.
18. Valle D, Kim-Schulze S, Huang H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020:1–8.
19. Escher R, Breakey N, Lammle B. Severe COVID-19 infection associated with endothelial activation. Thorax Res. 2020;190:62.
20. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020.
21. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020.
22. Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):S33–S46.
23. Gian Z, Travanty EA, Oko L, et al. Innate immune response of human alveolar type ii cells infected with severe acute respiratory syndrome–coronavirus. Am J Respir Cell Mol Biol. 2013;48(8):742–748.
24. Kase Y, Okano H. Expression of ACE2 and a viral virulence-regulating factor CCN family member 1 in human iPSC-derived neural cells: implications for COVID-19-related CNS disorders. Inflammation Regeneration. 2020;40(1):1–8.
25. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet North Am Ed. 2020.
26. Gao L, Jiang D, Wen X-s, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21:1–7.
27. Khatri P, Gupta RK, Vats P, et al. Subclinical elevated B-type Natriuretic Peptide (BNP) indicates endothelial dysfunction contributing to hypoxia susceptibility in healthy individuals. Life Sci. 2020;266:118408.
28. Lee DH, Dane MJ, Van Den Berg BM, et al. Deeper penetration of erythrocytes into the endothelial glycoalyx is associated with impaired microvascular perfusion. PLoS One. 2014;9(5):e96477.
29. Uchimido R, Schmidt EP, Shapiro NI. The glycoalyx: a novel diagnostic and therapeutic target in sepsis. Critical Care. 2019;23(1):16.
30. Fox SE, Akmatbekov A, Harbert JB, Li G, Brown JO, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respiratory Med. 2020.
31. Sack KD, Kellum JA, Parikh SM. The angiopeptin-Tie2 pathway in critical illness. Crit Care Clin. 2020;36(2):201–216.
32. Reusch P, Barleon B, Weindel K, et al. Identification of a soluble form of the angiopeptin receptor Tie-2 released from endothelial cells and present in human blood. Angiogenesis. 2001;4(2):123–131.
33. Ignarro LJ, Nitric Oxide: Biology and Pathobiology. Academic press; 2000.
34. Aikaze T, Maeda H. Nitric oxide and virus infection. Immunology. 2000;101(3):300–308.
35. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost: 2020;18(4):841–847.
36. Lippi G, Mattuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Hematol, Transfus Cell Ther. 2020.
37. Cabrales P. Examining and mitigating acellular hemoglobin vasocoactivity. Antioxid Redox Signaling. 2013;18(17):2329–2341.
38. Rossaint R, Falke KJ, Lopez F, Slamka P, Pison U, Zapal WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328(8):390–405.
39. Chen L, Liu P, Gao H, et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis. 2004;39(10):1531–1535.
40. Lee H-Y, Zeeshan HMA, Kim H-R, Chae H-J. Nox4 regulates the eNOS uncoupling process in aging endothelial cells. Free Radical Biol Med. 2017;112:26–35.
41. Cseoma B, Bikov A, Nagy L, et al. Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD. Respir Res. 2019;20(1):156.
42. Afshari A, Brok J, Møller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesthesia Analg. 2011;112(6):1411–1421.

43. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, MO Meade. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ. 2007;334(7597):779.

44. Zamanian RT, Pollack Jr CV, Gentile MA, et al. Outpatient inhaled nitric oxide in a patient with vasoreactive IPAH and COVID-19 infection. Am J Respir Crit Care Med. 2020. ja.

45. Nacharaju P, Tuckman-Vernon C, Maier KE, et al. A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: sustained vascular response. Nitric Oxide. 2012;27(3):150–160.

46. Navati MS, Lucas A, Liong C, et al. Reducing ischemia/reperfusion injury by the targeted delivery of nitric oxide from magnetic-field-induced localization of S-nitrosothiol-coated paramagnetic nanoparticles. ACS Appl Bio Mater. 2019;2(7):2907–2919.

47. Williams AT, Muller CR, Govender K, et al. Control of systemic inflammation through early nitric oxide supplementation with nitric oxide releasing nanoparticles. Free Radical Biol Med. 2020;161:15–22.